1. Positive video news report on the first child treated for...

1. Positive video news report on the first child treated for MIS-C including a brief interview with one of the treating doctors.
Doctor: “What’s really exciting about this particular product (remestemcel-l) is that it’s more specific than a lot of the current treatments we have.”

https://www.wbtw.com/health/coronav...cation-after-a-first-in-the-nation-treatment/

2. Interesting discussion on the drugs/treatments listed for decision by the FDA in September.

https://www.evaluate.com/vantage/ar...-no-go-quiet-month-ahead-us-approval-verdicts

3.Following the Friday morning preso, many posts here on the possible impact of improved standard of care in the ARD’s trial.

All I can add is to reiterate some data I posted recently. (Note, this is European, not U.S. data, and a typo has been amended)

“There’s been a fair bit of speculation here about what effect improved standard of care will have on 30 day mortality in the placebo group of MSB’s Covid-19 ARD’s trial. A large study from Spain, published a few days ago, could give some clues.

From March 12th to June 1st this year, the researchers followed the progress of 742 patients, aged 18+, in 36 ICU’s. All were followed from the first day of mechanical ventilation and the analysis included 28 day mortality.

The patients were all grouped into either mild (128), moderate (331) or severe (283) ARD’s with the same Berlin scale used in the MSB trial.

The researchers noted that most patients experienced improved recent SOC treatments including proning. No evidence I could see of stem cell treatment though. There were some other differences for example 11 in the severe group and 9 in the moderate group were on ECMO, an exclusion factor in MSB’s trial. Also, 30 day mortality, rather than 28, is analysed in the MSB trial and mild ARD’s patients are ineligible.

Nonetheless, as a point of comparison, imo the data from this trial is still very useful .

28 day mortality in the Spanish trial was 39% (111/283) in severe and 29% (99/331) in moderate ARDs.

Definitely food for thought.”

https://link.springer.com/article/10.1007/s00134-020-06192-2

Herro.